Paroxysmal Nocturnal Hemoglobinuria Pipeline Analysis: 20+ Key Companies Advancing the Future of PNH Therapeutics | DelveInsight

DelveInsight's "Paroxysmal Nocturnal Hemoglobinuria Pipeline Insight, 2026" report provides comprehensive global coverage of available, marketed, and pipeline therapies for Paroxysmal Nocturnal Hemoglobinuria (PNH) in various stages of clinical development. Major pharmaceutical and biotechnology companies are actively working to advance the PNH pipeline landscape and improve future treatment opportunities for patients worldwide.

Key takeaways from the Paroxysmal Nocturnal Hemoglobinuria Clinical Trial Landscape Report
• DelveInsight's Paroxysmal Nocturnal Hemoglobinuria pipeline report depicts a robust space with multiple active players working to develop innovative therapies for PNH treatment.
• Key Paroxysmal Nocturnal Hemoglobinuria companies such as Regeneron Pharmaceuticals, Novo Nordisk, Kira Pharmaceuticals, NovelMed Therapeutics, ADARx Pharmaceuticals, and Nanjing Chia-tai Tianqing Pharmaceutical are evaluating novel therapeutic approaches for PNH management.
• Promising Paroxysmal Nocturnal Hemoglobinuria pipeline therapies in various stages of development include Pozelimab, Zaltenibart, KP104, ADX-038, NM5072, and NTQ5082.

Request a sample and discover the recent advances in Paroxysmal Nocturnal Hemoglobinuria treatment drugs https://www.delveinsight.com/sample-request/paroxysmal-nocturnal-hemoglobinuria-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Paroxysmal Nocturnal Hemoglobinuria?
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare, acquired clonal hematopoietic stem cell disorder characterized by complement-mediated destruction of red blood cells, bone marrow failure, and an increased risk of thrombosis. The disease is caused by somatic mutations in the PIGA gene, leading to deficiency of GPI-anchored complement regulatory proteins such as CD55 and CD59 on blood cells. Common symptoms include fatigue, pallor, shortness of breath, abdominal pain, dysphagia, headaches, and dark-colored urine due to hemoglobinuria. Diagnosis is primarily based on flow cytometry demonstrating reduced expression of GPI-anchored proteins, along with laboratory evidence of hemolysis. Current treatment approaches include complement inhibitors, supportive care, anticoagulation, and stem cell transplantation in severe cases.

Emerging Paroxysmal Nocturnal Hemoglobinuria Drug Profiles
Pozelimab: Regeneron Pharmaceuticals
Pozelimab is an investigational monoclonal antibody developed by Regeneron Pharmaceuticals for the treatment of PNH. The therapy targets complement component C5 and inhibits terminal complement activation responsible for intravascular hemolysis. Pozelimab is being evaluated both as monotherapy and in combination with cemdisiran to provide sustained complement inhibition. The therapy is currently in Phase III clinical development for PNH treatment.
KP104: Kira Pharmaceuticals
KP104 is an investigational recombinant fusion protein therapy being developed for the treatment of PNH. The therapy is administered intravenously and subcutaneously and is currently in Phase II clinical development. KP104 is designed to regulate complement pathway activation and improve disease control in PNH patients.

Learn more about the novel and emerging Paroxysmal Nocturnal Hemoglobinuria pipeline therapies https://www.delveinsight.com/sample-request/paroxysmal-nocturnal-hemoglobinuria-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the Paroxysmal Nocturnal Hemoglobinuria Clinical Trial Landscape
• In December 2024, Regeneron Pharmaceuticals announced positive updated Phase III data from the ACCESS-1 trial investigating the pozelimab and cemdisiran combination treatment in PNH patients.
• In March 2023, Regeneron Pharmaceuticals initiated an open-label extension Phase III study evaluating the long-term safety, tolerability, and efficacy of pozelimab and cemdisiran combination therapy in patients with PNH.
• In May 2025, NovelMed announced positive 12-week interim Phase II results for Ruxoprubart in adult patients with PNH, demonstrating transfusion avoidance, increased hemoglobin levels, and reduced LDH levels.
• In March 2025, Omeros Corporation reported that clinical trial site activation for enrollment was underway for its Phase III program evaluating Zaltenibart (OMS906) in PNH patients.

Scope of the Paroxysmal Nocturnal Hemoglobinuria Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase I/II, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral
• Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Recombinant Fusion Protein, Oligonucleotide, Small Molecule
• Key Paroxysmal Nocturnal Hemoglobinuria Companies: Regeneron Pharmaceuticals, Novo Nordisk, Kira Pharmaceuticals, NovelMed Therapeutics, ADARx Pharmaceuticals, Nanjing Chia-tai Tianqing Pharmaceutical, and others
• Key Paroxysmal Nocturnal Hemoglobinuria Pipeline Therapies: Pozelimab, Zaltenibart, KP104, ADX-038, NM5072, NTQ5082, and others

Dive deep into rich insights for new drugs for Paroxysmal Nocturnal Hemoglobinuria treatment, visit https://www.delveinsight.com/sample-request/paroxysmal-nocturnal-hemoglobinuria-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Paroxysmal Nocturnal Hemoglobinuria Pipeline Report Introduction
2. Executive Summary
3. Paroxysmal Nocturnal Hemoglobinuria Overview
4. Pipeline Therapeutics
5. Late Stage Products (Phase III)
6. Mid Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Early Stage Products (Phase I)
9. Preclinical Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Paroxysmal Nocturnal Hemoglobinuria Unmet Needs
14. Paroxysmal Nocturnal Hemoglobinuria Market Drivers and Barriers
15. Appendix
16. About DelveInsight

For further information on the Paroxysmal Nocturnal Hemoglobinuria pipeline therapeutics, reach out https://www.delveinsight.com/sample-request/paroxysmal-nocturnal-hemoglobinuria-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.